PERSEVERA BC
What it tests: Giredestrant + palbociclib vs letrozole + palbociclib as 1L therapy in ER+ HER2− LA/MBC (phase III)
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.